Clinical lung cancer · 2025
Clinical Outcomes and Predictive Factors in NSCLC after Surgery: Findings from the RAC-TAC Study.
СтатьяМногоцентровое исследованиеНаблюдательное исследованиеНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Bruni Alessio, Franceschini Davide, Marini Beatrice, Vagge Stefano, Ciammella Patrizia, Sepulcri Matteo, Grassi Roberta, Gagliardi Federico, Cappelli Anna, D'Angelo Elisa, Manetta Mattia, Scricciolo Melissa, Guida Cesare, Fazio Ivan, Borghetti Paolo, Cappabianca Salvatore, Nardone Valerio
Аннотация
PURPOSE: Recent trials like LUNG-ART and PORT-C have redefined postoperative radiation therapy (PORT) for pN2 non-small cell lung cancer (NSCLC). To assess the acute and long-term toxicities of contemporary PORT techniques, the Italian Association of Radiotherapy and Oncology Lung Cancer Study Group initiated a multicenter observational study, analyzing clinical factors influencing local control, distant control, and overall survival.
METHODS: Data from 6 Italian centers were reviewed for NSCLC patients undergoing PORT between 2015 and 2020. Acute and late toxicity outcomes were previously reported. This study correlates clinical variables with local recurrence, distant recurrence, and survival outcomes.
RESULTS: Local recurrence correlated with the number of lymph nodes removed (P = .003) and patient age (P = .006). Distant recurrence was linked to the number of positive lymph nodes (P = .001) and T stage (P = .009). Overall survival was significantly associated with the number of positive nodes (P = .006) and ECOG performance status (P < .001). A risk stratification system categorized patients into low, intermediate, and high-risk groups, with the low-risk group showing significantly better progression-free survival (P < .001), distant control (P = .004), and overall survival (P = .008).
CONCLUSIONS: Distant metastases remain the main recurrence type. The extent of lymph node dissection and the count of positive nodes significantly influence recurrence patterns. These findings support integrating systemic and local therapies to improve outcomes in pN2 NSCLC.
METHODS: Data from 6 Italian centers were reviewed for NSCLC patients undergoing PORT between 2015 and 2020. Acute and late toxicity outcomes were previously reported. This study correlates clinical variables with local recurrence, distant recurrence, and survival outcomes.
RESULTS: Local recurrence correlated with the number of lymph nodes removed (P = .003) and patient age (P = .006). Distant recurrence was linked to the number of positive lymph nodes (P = .001) and T stage (P = .009). Overall survival was significantly associated with the number of positive nodes (P = .006) and ECOG performance status (P < .001). A risk stratification system categorized patients into low, intermediate, and high-risk groups, with the low-risk group showing significantly better progression-free survival (P < .001), distant control (P = .004), and overall survival (P = .008).
CONCLUSIONS: Distant metastases remain the main recurrence type. The extent of lymph node dissection and the count of positive nodes significantly influence recurrence patterns. These findings support integrating systemic and local therapies to improve outcomes in pN2 NSCLC.